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Abstract
Background: Sepsis and complications to sepsis are major causes of mortality in critically ill
patients. Rapid treatment of sepsis is of crucial importance for survival of patients. The infectious
status of the critically ill patient is often difficult to assess because symptoms cannot be expressed
and signs may present atypically. The established biological markers of inflammation (leucocytes, C-
reactive protein) may often be influenced by other parameters than infection, and may be
unacceptably slowly released after progression of an infection. At the same time, lack of a relevant
antimicrobial therapy in an early course of infection may be fatal for the patient. Specific and rapid
markers of bacterial infection have been sought for use in these patients.
Methods: Multi-centre randomized controlled interventional trial. Powered for superiority and
non-inferiority on all measured end points. Complies with, "Good Clinical Practice" (ICH-GCP
Guideline (CPMP/ICH/135/95, Directive 2001/20/EC)). Inclusion: 1) Age ≥ 18 years of age, 2)
Admitted to the participating intensive care units, 3) Signed written informed consent.
Exclusion: 1) Known hyper-bilirubinaemia. or hypertriglyceridaemia, 2) Likely that safety is
compromised by blood sampling, 3) Pregnant or breast feeding.
Computerized Randomisation: Two arms (1:1), n = 500 per arm: Arm 1: standard of care. Arm 2:
standard of care and Procalcitonin guided diagnostics and treatment of infection.
Primary Trial Objective: To address whether daily Procalcitonin measurements and immediate
diagnostic and therapeutic response on day-to-day changes in procalcitonin can reduce the
mortality of critically ill patients.
Discussion: For the first time ever, a mortality-endpoint, large scale randomized controlled trial
with a biomarker-guided strategy compared to the best standard of care, is conducted in an
Intensive care setting. Results will, with a high statistical power answer the question: Can the
survival of critically ill patients be improved by actively using biomarker procalcitonin in the
treatment of infections? 700 critically ill patients are currently included of 1000 planned (June 2008).
Two interim analyses have been passed without any safety or futility issues, and the third interim
analysis is soon to take place. Trial registration number at clinicaltrials.gov: Id. nr.: NCT00271752).
Background
1.1. Sepsis in the Intensive Care Unit
Sepsis caused by bacteria is the major cause of mortality in
ICU-patients. Rapid initiation of the correct treatment is
of crucial importance for the probability for surviving the
condition [1,2].
Bacterial sepsis in ICU patients is a condition that 1) is
complex to diagnose, 2) hard to monitor regarding treat-
ment effect, 3) very frequent in these patients and 4) car-
ries a high mortality risk for the patient, if treatment is not
adjusted precisely and rapidly, when treatment failure is
eminent.
Reasons for this can be:
1) Symptoms are rarely expressed, since many
ICU.patients are unconscious.
2) Clinical findings have often got an atypical appearance
because of an immunological incompetence and because
of the treament regimens (dialysis, intropic drugs a.s.o.).
3) The established infection markers, Leucocytes and C-
reactive protein, are influenced by many other conditions
than bacterial infection, and they are released to the blood
steam with a considerable delay of time.
Specific and rapid markers for sepsis have therefore been
sought for monitoring of ICU-patients through many
years.
Procalcitonin as a marker for Sepsis
Serum-Procalcitonin (PCT) is a sensitive and specific
biomarker for bacterial sepsis, and the level of PCT
increase is correlated to the severity of the infection [3,4].
It is documented that PCT release to the blood stream is
initiated 2–6 hours after bacteria or bacterial products are
presented in the blood [5], which is faster than the estab-
lished markers. The PCT level increases transiently, (in
opposition to C-reactive protein (CRP) and leucocytes)
for only 12–24 hours after surgery, if hvis the patient is
not developing an infection. If the PCT level increases for
more than 24 hours after surgery, bacterial sepsis should
be suspected [6,7]. Our group has earlier shown that theBMC Infectious Diseases 2008, 8:91 http://www.biomedcentral.com/1471-2334/8/91
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mortality rate in ICU patients is increased markedly from
day-to-day, when the PCT level increases [8]. Approxi-
mately 10.000–15.000 patients are admitted to ICU's in
Denmark every year. 3000–4000 of these die in connec-
tion to this ICU admittance and a large part of these
deaths are attributable to bacterial sepsis (assumed from
numbers from the Grand Capital Region).
Globally, no randomized interventional studies have
been conducted with the aim to reduce mortality in the
ICU by guiding the treatment of infections with daily PCT
measurements.
Followingly, there is at the present time, not satisfying evi-
dence to implement PCT-measurements in the everyday
practice in ICU-departments [9].
1.2. Study Aim
Primary
aim: To investigate whether a treatment strategy, that is
guided by daily measurements of the infection biomarker
"Procalcitonin" can reduce the mortality rate in intensive
care unit (ICU) patients. Apart from this, secondary aims
concern reducing several early and late complications to
infection, hospitalization and antibiotic comsumption.
1.3. Hypothesis
Daily measurements of the infection biomarker Procalci-
tonin can precisely and in a timely manner monitor the
emergence and the course of a serious infection in ICU
patients and can via rapid and sufficient changes in the
diagnostics and therapeutics increase the survival rate.
Methods
2.1. Design and sample size
Multi-centre randomized controlled single blinded inter-
ventional trial. Powered for superiority and non-inferior-
ity on all measured end points. Complies with, "Good
Clinical Practice" (ICH-GCP Guideline (CPMP/ICH/135/
95, Directive 2001/20/EC)) and all applicable regulatory
requirements.
Initially the patient is randomized either to "PCT-guided
treatment" or "The Control Group".
All included patients have blood samples made every
morning (including weekends, national holidays etc.).
Sample size
With a sample size of 500 per group and an assumed mor-
tality rate of 25% in the control group and 17.5% in the
PCT group there will be 80% probability that a negative
result (Confirming the Null Hypothesis) is true. At the
same time there will be < 5% probability of falsely declar-
ing the alternative hypothesis correct. [Power 80%, strin-
gency 5%].
The sample size calculation is made in cooperation with
Dep. of Statistics, UCLA and Jim Neaton, Ph.D. Professor,
Division of Biostatistics, Biometry, University of Minne-
sota, both USA.
The Study Design has been chosen from its strength to
investigate the study aim. The Study Group has a large and
thorough experience with randomized interventional tri-
als, since the initiating powers with Professor Jens D. Lun-
dgrens as a leading power has lead and completed several
randomized controlled trials, and members of the study
group are presently engaged in other studies with this
design.
2.2. Patients
Inclusion
A subject will be eligible for inclusion in this trial only if
all of the following criteria apply: 1) Male or female, aged
≥ 18 years of age, 2) Admitted to the participating inten-
sive care units. Patients should be included within 24 h. If
a patient has not been included at this time, this patient
cannot be included in the present admittance, 3) Subjects
should in the investigator's opinion be likely to be admit-
ted to the ICU for more than 24 h. Subjects should not be
likely (<10%) to die or be discharged in this period of
time, 4) Ability to understand and provide written
informed consent to participate in this trial, or ability to
understand and provide oral informed consent in pres-
ence of at least one impartial witness who should sign and
personally date the consent form or the subject's legally
acceptable representative can understand and provide
written informed consent if the subject is not capable of
this because of the present mental or physical condition of
the subject.
Exclusion
A subject will NOT be eligible for inclusion in this trial if
any of the following criteria apply:
1) Subjects with known hyper-bilirubinaemia (>0.4 mg/
ml) or hypertriglyceridaemia (>10 g/l) since this can inter-
fere with measurements. If subjects with unknown status
on these points are included and have PCT measure-
ments, the measuring-equipment will detect these condi-
tions, 2) Subjects suffering from a blood disorder, where
daily sampling of 7 ml of blood for maximally 28 days
(210 ml distributed on 28 days) will be an inconvenience
or a potential risk, which could compromise the safety of
the subject.
2.3. Scientific participants, organisation
The study group consists of physicians from all the partic-
ipating ICU's, Dept.'s of Clinical Microbiology and from
specialists in infectious medicine. The study group has a
solid research experience, with numerous publications in
the best international journals.BMC Infectious Diseases 2008, 8:91 http://www.biomedcentral.com/1471-2334/8/91
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2.4. Randomization and blinding
The randomisation is performed via computer, on-line to
the PASS study centre and is stratified according to site,
age and initial Acute Physiology And Chronic Health Eval-
uation II (APACHE II) score. For patients randomised to
the PCT intervention arm, daily PCT levels are communi-
cated to the team responsible for the clinical management
together with a recommendation of what interventions
the investigator team is expected to initiate based on the
PCT measurement. In the control arm, blood samples for
PCT will be analysed simultaneously with samples from
the PCT intervention arm, but results of these PCT analy-
ses will remain blinded for the investigators until the
study has been completed. The PCT measurements will be
conducted daily as long as the patient is admitted to the
ICU, but maximally 28 days from time of enrolment in
this study. Patients transferred from one ICU to another
ICU, will remain in the trial provided that the receiving
ICU also participates in this trial.
2.5. Treatment and Intervention
The aim of the PCT guided treatment is to reduce time to
relevant treatment of a serious infection and thereby to
reduce the mortality. All subjects will receive the standard-
of-care evaluations and therapeutic interventions recom-
mended in the ICU at which the patient is admitted to.
Subjects in the PCT measurement group will additionally
receive expanded diagnostics and treatment should the
PCT levels be found to high and/or increasing (see section
3.3.1 for definitions).
Access to results of PCT measurements of any kind (semi-
quantitative or quantitative) at any time in the study
period is not allowed for patients randomised to the con-
trol arm.
The PASS study group in collaboration with the PASS
Steering Committee, will issue guidelines for the compo-
sition of the interventions that a high or increasing PCT
level would mandate. Some variation between sites is
acceptable, whereas all patients within a given ICU should
follow that ICU's guidelines. The guidelines will be
updated when new information becomes available. In the
guidelines, there may be several alternatives indicated for
a given situation. The investigator is not mandated to fol-
low the guidelines.
Antimicrobial interventions – principles
The investigator or an intensive care physician, who has
been sufficiently instructed in all aspects of the trial, must
prescribe all antimicrobial drugs that are prescribed on
basis of an increasing PCT. The investigator must check for
possible drug-drug interactions between any of the drugs
prescribed guided by PCT changes and other agents that
may be metabolised via the same enzyme systems or
organs. To assist the investigator, information on this
topic is included in the Manual of Operational Proce-
dures. Also, the product label of each drug prescribed
should be reviewed.
General principles that will be followed regarding antimi-
crobial therapy of sepsis are:
▪ Antimicrobial agents are prescribed, when possible,
according to the resistance pattern of the causative micro-
organism.
▪ When the causative microorganism is not known, anti-
microbial agents are prescribed according to knowledge of
which microorganisms normally and possibly infect the
suspected focus.
▪ When neither the microorganism nor the focus of infec-
tion is known, one or more broad-spectrum antimicrobial
agents are selected. If the effect is not sufficient, the spec-
trum of the used antimicrobial agents is additionally
expanded, often with anaerobic active agents, gram-posi-
tive active agents and antifungal agents. Conversely, if the
effect is sufficient, the spectrum of used antimicrobial
agents is narrowed according to knowledge of focus and
causative microorganism.
▪ In empiric sepsis treatment, a combination of a β-
lactam/Carbapenem + a fluor-quinolone is chosen if not
contra indicated in the specific subject. This treatment can
be supplemented with nitroimidazoles, glycopeptides,
oxazolidinones and azoles. More specific treatment
regimes are initiated and guided by findings regarding the
causative microorganism and/or focus of infection.
▪ Dosages of antibiotics are decided according to the rec-
ommendations of the specific ICU.
The toxicity management guidelines detailed below refer
to all components of the antimicrobial treatment used in
the trial.
Overdose and Toxicity
Antimicrobial agents may be interrupted because of the
development of adverse events (AE) at the discretion of
the investigator and according to the severity of the AE.
The dose of all antimicrobial drugs may be reduced, inter-
rupted or reintroduced according to standard practice at
the time, and depending on the severity of the AE.
Subjects who require a dose modification should be re-
evaluated on a daily basis.
The investigator is responsible for taking appropriate pre-
cautions to ensure that the risk of developing toxicity is
minimised.BMC Infectious Diseases 2008, 8:91 http://www.biomedcentral.com/1471-2334/8/91
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Procalcitonin levels and diagnostic and therapeutic consequenses
The situation mandating additional interventions in the
the PCT intervention arm is based on the following crite-
ria: → PCT levels > 1.00 ng/ml and the PCT level increases
one day to the next or has an "irrelevant" decrease of <
10%. The daily assessment of PCT guided interventions
will be as follows:
A) Subjects with PCT levels > 1.00 ng/ml based on the first
determination after enrolment into the study will follow
the principles for interventions as detailed below.
B) Subjects with PCT levels > 1.00 ng/ml and with a day
(n) to day (n+1) PCT increase or a decrease of < 10%
(irrelevant decrease) will follow the principles for inter-
ventions as detailed below.
1) Microbiology: blood cultures, airway cultures, urine
cultures and samples from any other suspected foci, 2)
Considerations of whether to perform diagnostic imag-
ing: one or more of the following: Chest X-ray, Ultra-sonic
examination of suspected focus, Computerised Tomogra-
phy of relevant areas, Magnetic Resonance imaging of rel-
evant areas, other imaging techniques, 3) Surgical
drainage of possible un-drained foci, 4) Antimicrobial
therapy expansion. Treatment will be guided by any rele-
vant findings: microbial or diagnostic imaging, or other
findings. If focus and microorganism of infection is not
clear, steps will be: A) Empirical sepsis treatment, B)
Empirical sepsis treatment with anaerobic and gram posi-
tive coverage, C) Empirical sepsis treatment with anaero-
bic and gram positive coverage and/or fungal treatment.
Subjects with PCT levels < 1.00 ng/ml will continue to
receive standard-of-care. Subjects with PCT levels >1.00
ng/ml and with a day-to-day PCT decrease of > 10% will
continue to receive standard-of-care.
Precise guidelines for this (antimicrobial) treatment will
be made specifically for every ICU in concordance with
the local choices regarding antimicrobial agents. For PCT
guided diagnostics and treatment algorithm, see Fig 1.
Daily PCT analizing results
PCT-analysis is delivered before 11 A.M every morning,
but only for patients in the "PCT-guided group", (i.e. not
control group). When the PCT answer is delivered, all
PCT-guided patients are set in a "PASS-category". This cat-
egory carries a specific diagnostic and therapeutic pro-
gramme, aimed on improving the treatment of an
emerging infection, where there is treatment failure. In
this way, as hypothesized, the treatment is expanded to
cover the causative micro organism, even before the
patient comes to suffer from organ failure, circulatory col-
laps etc.
2.6. Data collection
Data is collected in Case Report Forms (CRF), which are
specific for every patient. CRF's are quality controlled by
an internal as well as an external control organisation, and
is then entered into the PASS-database. For overview of
data collection, see table 1.
Pre-entry Evaluations
The site must obtain subject consent in the form of a writ-
ten informed consent form prior to the initiation of any
pre-entry procedures as outlined in this protocol. The con-
sent form must be approved by the IEC of each participat-
ing site. The pre-entry evaluation will be conducted the
first day of the trial by an investigator in the ICU and will
include an evaluation of whether the patient fulfils the
requirements for enrolment in this trial.
Subjects who fail to meet the entry criteria may not be re-
screened for this protocol until 28 days after the failed pre-
entry evaluation. Hence, enrolment of such patients will
require that the patient is re-admitted to the ICU after at
least 7 days outside of the ICU after the time of the first
screening.
Baseline (Day 1) Evaluations
The following evaluations should be performed at base-
line (Day 1):
Note: For this trial, Baseline (Day 1) is defined as the day
on which the subject has his/her first blood sample for
PCT measurement. The following data are to be collected
on day 1: A) Demography including date of birth, weight,
height, and indication for admittance to the ICU, B) Infec-
tions found in the subject in this hospital admission prior
to admittance to the ICU, C) Present infection focus/etio-
logic microorganism, D) APACHE II score (Temperature,
Mean Arterial Pressure, Heart Rate, Respiratory Rate,
FIO2, HCO3-, pH (arterial), Se- Na+, K+, Creatinine, Hae-
matocrite, White Blood Count+ differential count, Glas-
gow Coma Scale) E) Current medical conditions, F) Pre-
admittance daily function and health state, G) Profes-
sional career 1) Student, 2) Part time work, 3) Full time
work, 4) Early retirement, 5) Retired. H) Health: 1) Con-
genital handicapped, 2) Acquired handicap, 3) Chronic
disabling disease, 4) Chronic non-disabling disease, 5)
Healthy, I) Self-supportance: 1) Lives in nursing home, 2)
Lives in a flat connected to a nursing home, 3) Own home
with external help ≥ once/day, 4) Own home with exter-
nal help < once daily, 5) Own home, no help required, J)
Hospital need: 1) ≥ 3 months admitted to a hospital/last
year, 2) 1–3 months admitted to a hospital/last year 3) 1–
30 days admitted/last year, 4) No admissions, ambulatory
visits ≥ 6/last year, 5) No admissions, ambulatory visits 1–
5/last year, 6) No admissions, No ambulatory visits/last
year, K) Adverse events/other complications to treatmentBMC Infectious Diseases 2008, 8:91 http://www.biomedcentral.com/1471-2334/8/91
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given in this hospital admission (ongoing clinical condi-
tions at Day 1 shall be recorded in the "Adverse Event and
Medical Condition Form" of the CRF at this time, regard-
less of the fact that such conditions may not subsequently
be found to fulfil the definitions for an adverse event, L)
Haematology: haemoglobin, platelet count (WBC count
mentioned as part of APACHE II), M) Clinical chemistry:
Albumin, Bilirubin, Factor 2-7-9, Alanin Amino Trans-
ferase (ALAT)/Aspartate Amino Transferase (ASAT), Alca-
line Phosphatase, Creatinine, Carbamide, Na+, K+,
Phosphate, Ca2+, C-reactive protein (some are also men-
tioned as part of APACHE II), N) Baseline PCT: The daily
PCT determination is done real-time at the Department of
Clinical Biochemical Department, Hvidovre Hospital,
using the EC-approved measuring instruments and rea-
gents. For each subject, the same methodology should be
used throughout the trial period. The KRYPTOR® PCT
BRAHMS sensitive assay is the accepted standard assay.
Other licensed assays may be used instead if judged by the
PASS steering committee to have a comparable perform-
ance compared to the indicated assay.
On Trial Evaluations
On trial assessments will be completed at the following
time-points unless otherwise specified:
While admitted to the ICU, the following information
will be registered unless specified otherwise:
Daily while patient is admitted to the ICU: A) Clinical
signs of new (nosocomial) infections, B) Microbiological
or radiological evidence of new (nosocomial) infection,
C) Defined Day Doses of antimicrobial chemotherapy, D)
APACHE II score (Temperature, Mean Arterial Pressure,
Heart Rate, Respiratory Rate, FIO2, HCO3-, pH (arterial),
Se- Na+, K+, Creatinine, Haematocrite, White Blood
Count+ differential count, Glasgow Coma Scale), E)
Occurrence of sepsis, severe sepsis, septic shock, DIC.
Assessment of Glasgow Coma Scale, measurement of
Blood Pressure (systolic blood pressure < 90), days with
artificial ventilation, Factor 2-7-9 < 0.7, creatinine
(increase factor 3 from baseline), MODS, F) Adverse
events/other complications to treatment given in the ICU
(ongoing clinical conditions at Day 1 shall be recorded in
the "Adverse Event and Medical Condition Form" of the
CRF at this time, regardless of the fact that such conditions
may not subsequently be found to fulfil the definitions for
an adverse event, G) Haematology: haemoglobin, platelet
count WBC (WBC count also mentioned as part of
APACHE II), H) Clinical chemistry: Albumin, Bilirubin,
Factor 2-7-9, Alanin Amino Transferase (ALAT)/Aspartate
Amino Transferase (ASAT), Alcaline Phosphatase, Creati-
nine, Carbamide, Na+, K+, Phosphate, Ca2+, C-reactive
protein (some are also mentioned as part of APACHE II),
I) Blood sample for PCT determination, J) Diagnostic
imaging procedures performed, K) Non-routine micro-
biological sample taken, L) Surgical procedures per-
formed, M) Change in antimicrobial chemotherapy, N) At
the day of discharge from ICU or day of death or later:
Mortality and time of death, and the cause hereof: AUC-
Procalcitonin (at discharge from the ICU, will remain
blinded in the control arm), O) Discharge and post-dis-
charge daily function and health state (obtained on day
30 and 180): Professional career: 1) Student, 2) Part time
work, 3) Full time work, 4) Early retirement, 5) Retired, P)
Health:1) Congenital handicapped, 2) Acquired handi-
cap, 3) Chronic disabling disease, 4) Chronic non-disa-
bling disease, 5) Healthy, Q) Self-supportance: 1) Lives in
nursing home, 2) Lives in a flat connected to a nursing
home, 3) Own home with external help ≥ once/day, 4)
Own home with external help < once daily, 5) Own
home, no help required, R) Hospital need: 1) ≥ 3 months
admitted to a hospital/last year, 2) 1–3 months admitted
to a hospital/last year 3) 1–30 days admitted/last year, 4)
No admissions, ambulatory visits ≥ 6/last year, 5) No
admissions, ambulatory visits 1–5/last year, 6) No admis-
sions, No ambulatory visits/last year.
Strategy for dynamic Procalcitonin-guided treatment Figure 1
Strategy for dynamic Procalcitonin-guided treat-
ment. According to the kinetic/elimination prophile of pro-
calcitonin, a decrease of at least 10% pr. 24 h should be 
observed, when bacterial infection is under control.BMC Infectious Diseases 2008, 8:91 http://www.biomedcentral.com/1471-2334/8/91
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2.7. Interrim analyses
Interrim analyses are made at specified inclusion numbers
(250, 500, 750) and a Data and Safety Monitoring Board
elaborate the open reports from these. If an interim anal-
ysis gives reason for discontinuing the study from safety,
efficacy or futility reasons, notion will be taken, and a pro-
cedure for taking this step is described in detail in the
detailed protocol. Stopping the trial will not be based
purely on a statistical decision but also on the recommen-
dation of the DSMB.
2.8. Analyses and statistics
Efficacy and safety analyses are made on the "intention to
treat"-group. The main analysis of the primary endpoint
will be the comparison of the two differing treatment
strategies, regarding 28-day-mortality. The stratified log-
rank test and Kaplan-Meier estimates will be used. The
treatment effect on reduction of early and late emrging
complications to serious bacterial infection (severe sepsis,
septic shock, disseminated Intravasulat Coagulation
(DIC) and multi organ dysfunction syndrome will be
determined as well as the ability of the strategy to reduce
the consumption of antibiotics. The research unit, Copen-
hagen HIV Programme, which is the coordination centre,
has two biostaticians in the staff.
2.9. Time plan/Status
Recruitment start and study registration:
703 patients have been included until now (July 2008).
The PASS-study is registered at National Institutes of
Health (NIH), USA at trial registration: clinicaltrials.gov,
Id. nr.: NCT00271752. Recruitment of patients has started
in 8 intensive care units (Jan, June, Oct. 2006, Jan + May
2007 × 4). Planned study closure, Oct/Nov. 2008.
2.10. rocalcitonin-analyses
For PCT-analysis, a fully automated and highly sensitive
method, the, KRYPTOR® PCT BRAHMS, has been chosen.
The procedure is done every day in dept. of Clinical Micro-
biolgy at Hvidovre Hospital and at Skejby Hospital. When
the answer to the analysis is ready, the answers are sent
out to via the database to ensure blinding of PCT-analysis
in the control-arm. An interpretation frame and corre-
sponding treatment algorism is delivered to all ICU's at
each nescessary intervention.
Discussion
The PASS-Study is accepted by the relevant local and
national institutions in Denmark, which regulate clinical
research, so as the local Ethical Board, the Data monitor-
ing authorities. The research group behind the PASS-study
has completed a thorough ethical discussion regarding the
main ethical aspects in running randomized trials, with-
holding potentially beneficial treatment for control group
patients, conducting interventional trials on unconscious
patients and aspects regarding the need to conduct the
trial at this point in time.
Additionally the question of how a bio-bank should be
made in the ethically most correct way has also been dis-
cussed.
Table 1: Data registration at time points in the patient course in the intensive care unit.
Evaluation Day (screening & baseline) Day (counting after admission to ICU) (follow-up)
1 2 thru 28 or dis-charge Day = Discharge/death 28 30 60 90 180
Informed Consent X
Entry Criteria X
Demography X
APACHE II/SOFA X X X
Infections during this hospital 
admission
XX
Current medical conditions X X X
State of daily function and health X X X
Mortality X (X) X X X X
PCT X X X
AUCprocalcitonin X
Concurrent Medicationsa X X X XXX X
Haematology X X X
Clinical chemistry X X X
Adverse events Xa X
Serious Adverse Events Xa X X XXX X
All data are registrered real-time in case report forms and according to the Good Clinical Practice legislation and guidelines. Clinical and laboratory 
Evaluations
a Adverse events and serious adverse events are registered daily
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Main points from these discussions are noted in the
detailed protocol.
Adverse events (AE)
Adverse events will be tabulated by treatment group, max-
imum intensity, attributability to various antimicrobial
agents and by seriousness. Treatment related adverse
events that lead the subject to prematurely discontinue
one or more of the originally prescribed antimicrobial
agents will also be summarised.
Clinical chemistry and haematology results will be pre-
sented by summary statistics and quartile plots of meas-
ured results. Change from baseline for these results will
also be presented. Baseline is defined as the laboratory
data collected at Day 1 (before the first blood sample for
PCT analysis). Subjects must have both a baseline and an
"on treatment" measurement to be included in the change
from baseline analysis.
Treatment emergent toxicity grades will be presented for
each graded laboratory parameter by treatment group. A
graded toxicity is considered treatment emergent if it
develops or increases in intensity, post Day 1. Treatments
will include established and approved antimicrobial treat-
ments, which are already used daily in the participating
ICU's.
Concurrent medications and blood products will be sum-
marised by randomised treatment group.
Adverse events (AE) and Serious Adverse Events (SAE) – 
Discussion
As mentioned other places in this protocol, the direct
inconvenience for subjects in this study is sampling of 7
ml of whole blood daily in the same session as the routine
blood samples are made, every morning. Therefore it is
reasonable to expect that AE's and SAE's as a direct conse-
quence of this blood sampling will not occur. Indirect
AE's as a consequence of potential overly treatment are
likewise not likely to occur according to the available lit-
erature on the issue, especially because the most striking
result of the previously published RCT's is a reduction of
antibiotic exposure in the PCT-guided group. All interven-
tions, that are performed in this study are well-known,
thoroughly tested and accepted treatments, so it does not
seem reasonable to apply the same procedures for this
study regarding AE's as e.g. a study where a new drug is to
be assessed for safety (or effect).
Investigators will, however, have the opportunity to
report events, that they find unexpected, in the Case
Report Form (CRF). In this part of the CRF, it is possible
to classify unexpected events in groups of "relatedness" to
the antimicrobial treatment as "no relation", "unlikely
relation", "possibly related", "probably related" or "defi-
nitely related.
Serious unexpected events or unexpected events
Serious inexpected events and unexpected events, that can
be related to the antimicrobial treatment will in both
treatment groups be reported to the Danish Medicines
Agency "Lægemiddelstyrelsen" according to the Danish
legislation on this point.
The primary and the secondary endpoints that are regis-
tered daily in the case report form are all adverse events or
serious adverse events, i.e. death, complications to sepsis,
increased antibiotic exposition and prolonged hospital
stay. These are registered routinely and daily in the part of
the CRF dealing with effects of the treatments. At inclu-
sion, all patients in the study are threatened by potentially
lethal illnesses.
Scientific Perspective
Numerous observational studies argue, that there is a pos-
sible diagnostic and therapeutic value of PCT-measur-
ments at bacterial sepsis in the ICU, and implementation
of the method for bacterial sepsis has therefore been dis-
cussed for several years. No large scale interventional stud-
ies have been conducted with an ICU patient population.
If PCT measurements where to be implemented in all
ICU's in Denmark, the laboratory costs alone will carry an
expense per year of 800.000 € – 2.5 million €. This is a
large expense to add on for the health system, without the
suffient evidence for an effect of the method. At present,
there is not high-level evidence (level 1–2) to support
implementation of PCT measurements in the ICU, and at
the same time, there is not high-level evidence to refrain
from implementing this biomarker.
One of the following four situations will occur, if evidence
at a higher level is not obtained: 1) PCT measurements are
not implemented in the ICU, in spite of a clinically signif-
icant effect for the patient, 2) PCT measurements are not
implemented in the ICU, and there is no clinically signif-
icant effect for the patient, 3) PCT measurements in the
ICU are in fact implemented, in spite of no clinically sig-
nificant effect for the patient, 4) PCT measurements in the
ICU are in fact implemented, and there is, in fact, a clini-
cally significant effect for the patient.
Situations 1 and 3 above will have large negative conse-
quences for patients (1) or society (3). At present, there is
no evidence to reveal which situation will occur, since no
randomised controlled trials have been conducted to
show if mortality in critically ill patients can be reduced by
using a strategy of daily standardised Procalcitonin meas-
urements as an early detector of serious bacterial infec-
tion.BMC Infectious Diseases 2008, 8:91 http://www.biomedcentral.com/1471-2334/8/91
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If the PASS-study is concluded as planned, situations 2 or
4 can be chosen on the basis of evidence level 1 back-
ground.
Database and biobank
The PASS-Study will furthermore give rise to a unique
intensive care research database and biobank with 1000
patients, and blood samples frozen from every day of the
admission period on all of these patients. This material
will have a statistical and scientific power to conclude on
many hypotheses regarding the diagnostics and treatment
of critically ill patients.
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